Page 2 - Drayson Phd News Today

Investegate announcements from Sensyne Health PLC, Sensyne and OMNY Health Sign Teaming Agreement

Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate

  Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decisi...

Drayson Technologies Develops Next Generation Biometric Smart Cards Powered by Freevolt Energy Harvesting Innovate UK funded project enabled Drayson Technologies to develop "Plug-n-Play" reference designs of its Freevolt radio frequency energy harvesting technology, delivering 3x more power for biometric smart card applications in secure access, cryptocurrency, healthcare and finance Drayson Technologies today announces the completion its Smart Grant project, funded by Innovate UK, the UKs inno...

Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth   Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ("FY 2021"), and an outlook statement.   UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at l...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. ("Phesi"), the two

About Sensyne Health   www.sensynehealth.com   Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.  The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers r emote patient monitoring and real-time ...

12 March 2021 | 09:39am StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests. The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...